This Q&A was edited for clarity and length. Disclosure Matthew J. Matasar, MD, reported affiliations with Merck & Co, Inc; Genentech, Inc; Roche Holding AG; GlaxoSmithKline, PLC; Bayer AG; Pharmacyclics LLC; Janssen Pharmaceuticals; Seagen Inc; ImmunoVaccine Technologies, Inc; Takeda Pharmaceutical Company, Ltd; Juno Therapeutics, Inc; Teva Pharmaceutical Industries, Ltd; Rocket Medical, LLC; Daiichi Sankyo Company,…
Bispecific antibodies have revolutionized oncology. Andreas K. Klein, MD, a hematologist-oncologist at Tufts University School of Medicine in Boston, discusses the development of CD19xCD3 and CD20xCD3 bispecific antibodies and their clinical application in the treatment of hematologic malignancies.
Jaffer A. Ajani, MD, professor of medicine at The University of Texas MD Anderson Cancer Center in Houston, discusses immunotherapeutic strategies and protocols for the treatment of esophageal cancer.
Connie Lee Batlevi, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City, discusses the latest research on follicular lymphoma presented at the ASH 2021 Annual Conference.
Adam M. Brufsky, MD, PhD, FACP, an oncologist and professor of medicine at the University of Pittsburgh School of Medicine in Pennsylvania, provides insight into distinguishing HER2-negative from HER2-low breast cancer.
Roger Li, MD, a genitourinary oncologist at Moffitt Cancer Center, discusses advances in the development of targeted treatments for patients with metastatic urothelial carcinoma nonresponsive to chemotherapy and immunotherapy, or those ineligible for chemotherapy.
Patients with nonmetastatic castration-resistant prostate cancer (M0 CRPC) tend to have more aggressive disease. Jingsong Zhang, MD, PhD, a genitourinary oncologist and clinical researcher at Moffitt Cancer Center, discusses the latest androgen receptor blockers for M0 CRPC.
Andrew J. Cowan, MD, from the Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses advances in chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma.
Zofia Piotrowska, MD, a thoracic medical oncologist, explores the challenges of managing patients with EGFR exon 20 insertion mutations in non-small cell lung cancer.
Paul K. Paik, MD, a medical oncologist specializing in the care of patients with lung cancer at Memorial Sloan Kettering Cancer Center, in New York, discusses targeted therapies to treat patients with NSCLC harboring MET exon 14 skipping mutations.
